Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Exec Heads East To Take The Reins Of Cancer-Focused Start-up Agios

This article was originally published in The Pink Sheet Daily

Executive Summary

Calling it “the right time and the right opportunity,” Genentech’s cancer drug development expert David Schenkein plans to move on.

You may also be interested in...



Celgene Expands Agios Collaboration In Cancer Metabolism

Cancer metabolism specialist Agios extends research collaboration with Celgene, picking up an additional $20 million.

Celgene Expands Agios Collaboration In Cancer Metabolism

Cancer metabolism specialist Agios extends research collaboration with Celgene, picking up an additional $20 million.

Takeda's Alogliptin Suffers Major Setback, Delaying Drug Launch Until 2012 Or Later

Takeda announced June 27 that U.S. FDA had denied approval of its type 2 diabetes agent alogliptin, a potential blockbuster poised to compete with similar molecules from Merck and the team of Bristol-Myers Squibb and AstraZeneca. The setback will delay alogliptin's launch by at least three years - and possibly longer - depending on the additional studies required by regulators

Related Content

Topics

UsernamePublicRestriction

Register

PS069478

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel